Quick Answer
ENANTA PHARMACEUTICALS INC reported Revenue (ASC 606) of $65.32 million for fiscal year 2025.
ENANTA PHARMACEUTICALS INC Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $65.32M | -3.4% |
| 2024 | $67.64M | -14.6% |
| 2023 | $79.20M | -8.1% |
| 2022 | $86.16M | -11.2% |
| 2021 | $97.07M | -20.7% |
| 2020 | $122.47M | -40.3% |
| 2019 | $205.20M | -0.7% |
| 2018 | $206.62M | +101.0% |
| 2017 | $102.81M | +16.5% |
| 2016 | $88.27M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $18.61M | +9.8% | +1.6% |
| June 30, 2025 | $18.31M | +1.9% | +22.7% |
| March 31, 2025 | $14.93M | -12.5% | -12.0% |
| December 31, 2024 | $16.96M | -5.8% | -5.6% |
| June 30, 2024 | $17.97M | -4.9% | +5.4% |
| March 31, 2024 | $17.05M | -4.2% | -5.3% |
| December 31, 2023 | $18.00M | -23.7% | -4.7% |
| June 30, 2023 | $18.89M | -3.0% | +6.2% |
- ENANTA PHARMACEUTICALS INC showed a decrease of -3.4% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, ENANTA PHARMACEUTICALS INC’s revenue (asc 606) has declined by 26.0% (from $88.27 million to $65.32 million).
- The most recent figure is from ENANTA PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on November 19, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: